Related Experiment Video
Updated: Jul 19, 2026

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model
Published on: October 31, 2012
Gene therapy of surfactant protein B deficiency
Manish Kumar Aneja1, Carsten Rudolph
1Division of Molecular Pulmonology, Department of Pediatrics, Ludwig-Maximilians University, Lindwurmstrasse 2A, 80337 Munich, Germany.
Abstract:
Surfactant protein B (SP-B) is encoded by a single gene, and the mature protein is expressed by alveolar type II epithelial (ATII) cells of the lungs. Studies in transgenic mice and its hereditary deficiency in humans have established its indispensable role in postnatal survival. An established gene therapy regime for treating SP-B deficiency could overcome the limitations of surfactant replacement therapies or lung transplantation. Among the various viral and non-viral gene delivery tools available, only adenoviral vectors have been tested for delivering SP-B cDNA to the lungs of animal models. This review discusses the various vectors that are available for delivering therapeutic genes into ATII cells.
Related Concept Videos
Breathing
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Respiratory Syncytial Virus Disease
Gene Therapy
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
